A prospective, multicenter, randomized phase II study to evaluate the efficacy and safety of eculizumab in patients with guillain-barré syndrome (GBS): Protocol of Japanese eculizumab trial for GBS (JET-GBS)

JMIR Research Protocols

Volumn 5, Issue 4, 2016, Pages

  Yamaguchi, Nobuko ^a   Misawa, Sonoko ^b   Sato, Yasunori ^b   Nagashima, Kengo ^b   Katayama, Kanako ^a   Sekiguchi, Yukari ^b   Iwai, Yuta ^b   Amino, Hiroshi ^b   Suichi, Tomoki ^b   Yokota, Takanori ^c   Nishida, Yoichiro ^c   Kohara, Nobuo ^d   Hirata, Koichi ^e   Nishiyama, Kazutoshi ^f   Yabe, Ichiro ^g   Kaida, Ken Ichi ^h   Suzuki, Norihiro ⁱ   Nodera, Hiroyuki ^j   Tsuji, Shoji ^k   Koike, Haruki ^l   Kira, Jun Ichi ^m   Hanaoka, Hideki ^a   Kusunoki, Susumu ⁿ   Kuwabara, Satoshi ^b   more..

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

^f KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

ⁱ KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j UNIVERSITY OF TOKUSHIMA   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

^l NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m KYUSHU UNIVERSITY   (Japan)

ⁿ KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Antiganglioside antibody; Clinical trial; Complement activation; Eculizumab; Guillain Barr syndrome

Indexed keywords

EID: 85014083861     PISSN: None     EISSN: 19290748     Source Type: Journal    
DOI: 10.2196/resprot.6610     Document Type: Article

References (23)

1. Osler LD, Sidell AD. The Guillain-Barre syndrome; the need for exact diagnostic criteria. N Engl J Med 1960 May 12;262:964-969. [doi: 10.1056/NEJM196005122621905] [Medline: 14429234]
2. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005 Nov 5;366(9497):1653-1666. [doi: 10.1016/S0140-6736(05)67665-9] [Medline: 16271648]
3. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36(2):123-133 [FREE Full text] [doi: 10.1159/000324710] [Medline: 21422765]
4. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2014;CD002063(9). [doi: 10.1002/14651858.CD002063.pub6] [Medline: 25238327]
5. Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012;CD001798(7). [doi: 10.1002/14651858.CD001798.pub2] [Medline: 22786475]
6. Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2012 Jul;83(7):711-718. [doi: 10.1136/jnnp-2011-301882] [Medline: 22566597]
7. Kuwabara S, Yuki N. Axonal Guillain-Barre syndrome: concepts and controversies. Lancet Neurol 2013 Dec;12(12):1180-1188. [doi: 10.1016/S1474-4422(13)70215-1] [Medline: 24229616]
8. Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007 Apr 11;27(15):3956-3967 [FREE Full text] [doi: 10.1523/JNEUROSCI.4401-06.2007] [Medline: 17428969]
9. Susuki K, Yuki N, Schafer DP, Hirata K, Zhang G, Funakoshi K, et al. Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 2012 Jan;233(1):534-542 [FREE Full text] [doi: 10.1016/j.expneurol.2011.11.039] [Medline: 22178332]
10. Phongsisay V, Susuki K, Matsuno K, Yamahashi T, Okamoto S, Funakoshi K, et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J Neuroimmunol 2008 Dec 15;205(1-2):101-104. [doi: 10.1016/j.jneuroim.2008.09.016] [Medline: 18973956]
11. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V, French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012 Nov;8(11):643-657. [doi: 10.1038/nrneph.2012.214] [Medline: 23026949]
12. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007 Nov;25(11):1256-1264. [doi: 10.1038/nbt1344] [Medline: 17989688]
13. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013 Jun 6;368(23):2169-2181. [doi: 10.1056/NEJMoa1208981] [Medline: 23738544]
14. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004 Feb 5;350(6):552-559. [doi: 10.1056/NEJMoa031688] [Medline: 14762182]
15. Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008 May;131(Pt 5):1197-1208 [FREE Full text] [doi: 10.1093/brain/awm316] [Medline: 18184663]
16. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990;27 Suppl:S21-S24. [Medline: 2194422]
17. Sekiguchi Y, Uncini A, Yuki N, Misawa S, Notturno F, Nasu S, et al. Antiganglioside antibodies are associated with axonal Guillain-Barre syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 2012 Jan;83(1):23-28. [doi: 10.1136/jnnp-2011-300309] [Medline: 22010183]
18. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975 Mar;31(1):103-115. [Medline: 1100130]
19. Brown S, Thorpe H, Hawkins K, Brown J. Minimization: reducing predictability for multi-centre trials whilst retaining balance within centre. Stat Med 2005 Dec 30;24(24):3715-3727. [doi: 10.1002/sim.2391] [Medline: 16320287]
20. Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV, et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome. Neurology 2003 Nov 11;61(9):1282-1284. [Medline: 14610140]
21. Bensa S, Hadden RD, Hahn A, Hughes RA, Willison HJ. Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barre syndrome: a pilot study. Eur J Neurol 2000 Jul;7(4):423-426. [Medline: 10971602]
22. Garssen MP, van Koningsveld KR, van Doorn PA, Merkies IS, Scheltens-de Boer M, van Leusden JA, et al. Treatment of Guillain-Barre syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry 2007 Sep;78(9):1012-1013 [FREE Full text] [doi: 10.1136/jnnp.2006.102731] [Medline: 17702789]
23. Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996 May;39(5):625-635. [doi: 10.1002/ana.410390512] [Medline: 8619548]